Oncology

Renier Brentjens, MD, PhD, the chair of the department of medicine at Roswell Park Comprehensive Cancer Center, discussed the need to bring more innovations from nonclinical research to patients.

Renier Brentjens, MD, PhD, the chair of the department of medicine at Roswell Park Comprehensive Cancer Center, discussed his views on toxicities and costs associated with CAR-T, and when and how the field should address them.

Review top news and interview highlights from the week ending April 18, 2025.

Renier Brentjens, MD, PhD, the chair of the department of medicine at Roswell Park Comprehensive Cancer Center, discussed his view on how the cell therapy field should proceed with regard to innovation.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Renier Brentjens, MD, PhD, the chair of the department of medicine at Roswell Park Comprehensive Cancer Center, discussed the innovations necessary to make CAR-T therapy effective in solid tumor indications.

Review top news and interview highlights from the week ending April 11, 2025.

The chair of the department of medicine at Roswell Park Comprehensive Cancer Center discussed the need to bring more innovations from nonclinical research to patients.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The chair of the department of medicine at Roswell Park Comprehensive Cancer Center discussed his views on toxicities and costs associated with CAR-T, and when and how the field should address them.

The chair of the department of medicine at Roswell Park Comprehensive Cancer Center discussed his view on how the cell therapy field should proceed with regard to innovation.

In Episode 3 of ImmunoLogic, Marcela Maus, MD, PhD, discussed her research on CAR-T for treating glioblastoma.

The chair of the department of medicine at Roswell Park Comprehensive Cancer Center discussed the innovations necessary to make CAR-T therapy effective in solid tumor indications.

Review top news and interview highlights from the week ending April 4, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

Review top news and interview highlights from the week ending March 28, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

In observance of National Colorectal Cancer Awareness Month, held annually in March, we took a look back at news in cell therapy for colorectal cancer indications.

Review top news and interview highlights from the week ending March 21, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

CGTLive® took a closer look at the single-center, open-label study, which aims to assess the safety and efficacy of the CAR-T therapy.

Review top news and interview highlights from the week ending March 14, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

In Episode 2 of ImmunoLogic, Bruce Levine, PhD, discussed the current the risk-benefit-ratio for CAR-T therapy.